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Cellular cholesterol levels are tightly regulated and represent a balance of cholesterol uptake,
endogenous synthesis and efﬂux. Although the classic transcriptional regulations of cholesterol
metabolism by liver X receptors (LXRs) have been well studied, the potential effects of LXR-
responsive microRNAs (miRNAs) still need to be unveiled. Here, we describe that miR-26, an
LXR-suppressed miRNA, inhibits the expression of the ATP-binding cassette transporter A1 (ABCA1)
and ADP-ribosylation factor-like 7 (ARL7), two LXR target genes which play critical roles in
cholesterol efﬂux. These ﬁndings have not only ﬁgured out an alternative mechanism for LXR
regulation, but also provided a potential therapeutic target for cholesterol metabolic disorders.
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Atherosclerosis is the leading underlying cause of death
worldwide [1]. It is a progressive disorder wherein lipid-loaded
macrophages initially accumulate in the subendothelial space.
Subsequently, most of these macrophages convert to foam cells fol-
lowing uptake of modiﬁed lipoproteins and other cellular debris
[2–4]. The inability of macrophages to efﬂux sufﬁcient amounts
of engorged cholesterol to the reverse cholesterol transport (RCT)
pathway contributes signiﬁcantly to foam cells formation [4,5].
Understanding the molecular mechanisms governing lesion devel-
opment and macrophage cholesterol efﬂux will be essential to
unraveling the pathogenesis of atherosclerosis.
Previous studies have shown that LXRs function as nuclear
cholesterol sensors that are activated in response to elevated intra-
cellular cholesterol levels in multiple cell types. Once activated,
LXRs induce a battery of genes involved in cholesterol transport,
including ABCA1, ABCG1, ABCG5, ABCG8, apolipoprotein (apo) E,





0014, PR China. Fax: +86 571
).genes mediate the cholesterol efﬂux from macrophages and pro-
tects against the development of atherosclerosis. For examples,
ABCA1, a well known LXR target gene, promotes macrophage cel-
lular cholesterol efﬂux and maintains cellular sterol homeostasis
[10,11]. Deﬁciencies or mutations in this transporter lead to
defects in cholesterol efﬂux and cholesterol ester accumulation
in macrophages and increase the risk of developing cardiovascular
disease [12–14]. ARL7, a recently identiﬁed LXR target gene, has
previously been shown to transport cholesterol to the membrane
for ABCA1-associated removal and thus may be integral to the
LXR-dependent efﬂux pathway [15,16].
In addition to the classic transcription regulators of the choles-
terol metabolism, a class of non-coding RNAs termed miRNAs has
also emerged as critical regulators of gene expression, acting pre-
dominantly at the posttranscriptional level [17]. As noted, miRNAs
have newly recognized inﬂuences on cholesterol homeostasis.
miRNAs constitute a large family of small (18–25 nucleotides)
non-coding RNA molecules, single stranded in the mature form,
which are important posttranscriptional regulators of gene expres-
sion [17–19]. miRNAs typically control the expression of their
target genes by imperfect base pairing with the 30 untranslated
regions (30UTRs) of messenger RNAs (mRNAs) thereby inducing
repression of the target mRNA. This inhibition can occur by
transcripts destabilization, translational inhibition, or both
[19–21]. Several miRNAs such as miR-33, miR-122, miR-370 and
miR-758 have been implicated in regulating cholesterol meta-
bolism [22–24].lsevier B.V. All rights reserved.
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regulate cholesterol efﬂux and high-density lipoprotein (HDL) bio-
genesis by downregulating ABCA1 [24–28], bioinformatic analyses
indicated that ABCA1 has a very long 30UTR (3.3 kb) and more than
100 potential miRNA candidates. Our results also indicated that
other miRNAs participated in the regulation of cholesterol metab-
olism by targeting ABCA1. Here, we report that miR-26, which is
suppressed after LXR activation, could target two important regu-
lators (ABCA1 and ARL7) of the LXR-dependent cholesterol path-
way thus control cholesterol metabolism.
2. Materials and methods
2.1. Reagents
LXR agonist T0901317 was from Cayman Chemical Company
(Michigan, USA). The speciﬁc LXR agonist GW3965 was provided
by Peter Tontonoz (UCLA, USA). The miRNA mimics were from
GenePharma (Shanghai, China). The miRNA inhibitors and LXR siR-
NAs were from Dharmacon (ThermoFisher Scientiﬁc). The antibod-
ies against ABCA1 (clone AB1.G6) and ARL7 were purchased from
Abnova (Taipei, Taiwan). The transfection reagents Jet-Endo™,
Jet-PEI™ and INTERFERin™ were from Polyplus Transfection (Ill-
kirch, FRANCE).2.2. Cell culture and transfection
RAW264.7, THP-1, HEK293T and HepG2 cell lines were pur-
chased from American Type Culture Collection (ATCC) and main-
tained at 37 C (5% CO2, 95% air) in culture medium consisting of
DMEM supplemented with 10% FBS. Plasmids expressing full-
length murine LXRawere subcloned into the pBABE retroviral vec-
tor and packaged into retrovirus by transfection into Phoenix A
cells to generate LXRa-HA-pBABE retrovirus. RAW264.7 cells were
infected with pBABE or LXRa-HA-pBABE retrovirus and selected
with 6 lg/ml puromycin for 1 week to generate stable-transfected
cell line RAW-vector cells or RAW-LXRa cells, respectively. For li-
gand treatments, cells were cultured in DMEM supplemented with
1% FBS (low serum) and the synthetic LXR agonist T0901317
(1 lM) or GW3965 (1 lM). Jet-PEI™ was used to transfect plas-
mids into HEK293T cells and RAW264.7 cells according to the
manufacturer’s instructions. INTERFERin™ was used to transfect
miRNA mimics, miRNA inhibitors or LXR siRNAs into RAW264.7
cells according to the manufacturer’s instructions.2.3. RNA quantiﬁcation
Total RNA was extracted with TRIzol reagent (Invitrogen) fol-
lowing the manufacturer’s instructions. Real-time quantitative
RT-PCR analysis was performed using the LightCycler (Roche)
and SYBR RT-PCR kits (Takara). For miRNA analysis, reverse
transcription primer for miR-26a was 50-GTCGTATCCAGTG-
CAGGGTCCGAGGTATTCGCACTGGATACGACAGCCTA-30. Quantita-
tive PCR (q-PCR) primers were 50-ATGGCTTCAAGTAATCC-AGGA-
30 (forward) and 50-GTGCAGGGTCCGAGGT-30 (reverse). Similarly,
U6 small nuclear RNA was quantiﬁed by using its reverse primer
for RT reaction and its forward and reverse primers for
q-PCR, which were 50-CTCGCTTCGGCAGCACA-30 (forward) and
50-AACGCTTCACGAATTTGC-GT-30 (reverse). The relative expres-
sion level of miRNAs was normalized to the internal control U6
by using 2DDCt cycle threshold method [29]. For human and
mouse ABCA1 and ARL7 mRNA analysis, as well as the human
primary mir-26a mRNA analysis, the primer sequences are
available upon request. The relative expression level of ABCA1and ARL7 were normalized to the level of b-actin expression in
each sample.
2.4. Plasmid construction
The primary mir-26a-1 promoter luciferase reporter construct
was made by amplifying the 50UTR region of human CTDSPL by
PCR and cloning into the Bgl II and Mlu I sites of pGL3-enhancer
construct (Promega). The primers for primary mir-26a-1 promoter
were 50-CCGGAAGTGTCCTTTAATACTTTGGAG-30 (forward) and 50-
TTGGTCACCTGGGTGATGATGGC-30 (reverse). The ABCA1 30UTR
and ARL7 30UTR luciferase reporter constructs were made by
amplifying the human ABCA1 and ARL7 30UTR sequence by PCR
and cloning into the Xba I site of pGL3-promoter construct
(Promega). The primers for ABCA1 30UTR were 50-TGGAAGCTTA
GAACTGTACACGTGTG-30 (forward) and 50-CACGTGGCAGAGT
TTGTTGATTGT-30 (reverse). The primers for ARL7 30UTR were
50-GGAAGAAGTCCTTTGGAAATC-30 (forward) and 50-CCTGCAGG
CTGCTAACCACTGC-30 (reverse). The mutant ABCA1 and ARL7
30UTR luciferase reporter constructs were generated by converting
miR-26a binding site ‘‘TACTTGA’’ into ‘‘TTCATCA’’.
2.5. 30UTR luciferase reporter assay
HEK293T cells were cotransfected with plasmids and RNAs by
Jet-Endo™ according to the manufacturer’s instructions. Brieﬂy,
HEK293T were seeded into 96-well plates (15000 cells per well).
24 h later, the cells were cotransfected with 80 ng of ﬁreﬂy lucifer-
ase reporter plasmid, 10 ng of pRL-TK-Renilla luciferase plasmid,
and the indicated RNAs (ﬁnal concentration, 20 nM). After 24 h,
luciferase activities were measured by using the Dual-Luciferase
Reporter Assay System (Promega) according to the manufacturer0s
instructions. Data was normalized for transfection efﬁciency by
dividing ﬁreﬂy luciferase activity with that of Renilla luciferase.
2.6. Immunoblot
Cells were lysed using M-PER protein extraction reagent
(Pierce) supplemented with protease inhibitor mixture (Calbio-
chem). Protein concentrations of the extracts were measured with
a BCA assay (Pierce) and equalized with the extraction reagent.
Equal amounts of the extracts were loaded and subjected to
SDS–PAGE, transferred onto nitrocellulose membranes, and then
blotted.
2.7. Cholesterol efﬂux assays
RAW264.7 cells were seeded in 24-well plates (1  105 cells per
well) and transfected with control mimics or miR-26a mimics, or
with control inhibitor or miR-26a inhibitor by using INTERFERin™
according to the manufacturer’s instructions. After 24 h in com-
plete media, the cells were washed and incubated for an additional
12 h in DMEM supplemented with 10% LPDS and [3H]-cholesterol
(1 lCi/ml). After 16 h, the cells were washed with PBS and then
incubated in DMEM supplemented with 0.2% BSA for a 2 h equili-
bration period. Where indicated, the cells were incubated with
T0901317 (1 lmol/l) during radiolabeling and equilibration. To
determine cholesterol efﬂux, the cells were rinsed three times with
PBS and then incubated for 6 h in DMEM supplemented with 0.2%
BSA and, where indicated, either ApoAI (15 lg/ml) or FBS (10%).
Subsequently, the media was removed, the cells were washed with
PBS, and the radioactive content of the media and cells was deter-
mined by scintillation. Cholesterol efﬂux was determined by divid-
ing the radioactive content of the media by the sum of the
radioactivity in the cells and media.
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Statistical signiﬁcance was determined by Student’s t test, with
P values of 50.05 considered to be statistically signiﬁcant.
3. Results
3.1. Inverse correlation between miR-26 and ABCA1, ARL7 in LXR-
activated macrophages
Ligand activation of LXRs induced several genes that control the
cholesterol metabolism, including the known LXR target genes
ABCA1, Idol, SREBP-1c, FAS, AIM, PLTP and ARL7 [30].The induction
of LXR target genes mainly depends on transcriptional activation,
however, the posttranscriptional regulations also make contribu-
tions. We detected the reported miRNAs such as miR-33 [25–28],
miR-146a [31], miR-122 [32,33], miR-370 [34], miR-378 [35],
miR-27 [36] and miR-125a-5p [37], which either participated in
the regulation of cholesterol metabolism, or related to the athero-
sclerosis. Meanwhile, several highly predicted miRNAs that may
regulate LXR target genes were also detected. In order to increase
the responsibility to LXR activation, we constructed an LXRa stable
overexpressing cell line RAW-LXRa, which expressed high level of
LXRa (Fig. 1A). Upon treatment with pan-LXR agonist T0901317,
the LXR target genes ABCA1 and ARL7 were robustly induced, both
in RAW-LXRa cells, a mouse macrophage cell line and in THP-1
cells, a human macrophage cell line (Fig. 1B–E). However, two of
the candidate miRNAs, miR-26a and miR-26b, were downregulated
signiﬁcantly in both macrophage cell line (Fig. 1F and G and
Fig. S1). However, the other candidates were comparable with or
without LXR agonist treatment (Fig. S1). Meanwhile, by using other
LXR/RXR agonists to activate the LXR pathway, we also found
the downregulation of miR-26a expression in LXR-activatedFig. 1. miR-26 and LXR target genes expression in LXR-activated macrophages. (A) Weste
selected RAW264.7 cells. The results of three clones of RAW-LXRa cells were shown.
independent experiments. (B, C) Murine (RAW-LXRa) or human (THP-1) macrophage ce
were performed to detect the ABCA1 mRNA expression. (D, E) ARL7 mRNA expression in
cells described in (B, C) was detected by qPCR. ABCA1 and ARL7 mRNA was normalized to
independent experiments. ⁄⁄P < 0.01.macrophages (Fig. S2). Taken together, we found an inverse corre-
lation between miR-26 and two LXR target genes, ABCA1 and ARL7
in LXR-activated macrophages.
3.2. LXR-speciﬁc regulation of miR-26 was at transcriptional level
In order to determine whether the downregulation of miR-26
expression was LXR speciﬁc, we not only used a more speciﬁc
LXR agonist GW3965, but also knocked down the endogenous
LXR by using a mixture of siRNAs targeting LXRa and LXRb. miR-
26 expression was downregulated in GW3965-treated macro-
phages (Fig. S2). Higher miR-26a expression in LXR-silenced
RAW264.7 cells, no matter treated with T0901317 or GW3965
(Fig. 2A). The above results indicated that miR-26 suppression
was LXR speciﬁc in LXR-activated cells. To ﬁgure out the mecha-
nism which mediated the downregulation of miR-26 expression
in LXR-activated macrophages, we detected the primary mir-26a
mRNA. Two loci align with miR-26a in the human genome
[38,39]. mir-26a-1 is located in an intron of C-terminal domain
RNA polymerase II polypeptide A small phosphatase-like (CTDSPL)
at chromosome 3, andmiR-26a-2 is located in an intron of C-termi-
nal domain RNA polymerase II polypeptide A small phosphatase 2
(CTDSP2) at chromosome 12. Surprisingly, we found that only pri-
mary mir-26a-1 transcription was inhibited rather than mir-26a-2
in LXR-activated THP-1 cells (Fig. 2B and C). Given that mir-26a-1
located in the intron of CTDSPL, we cloned about 2000 bp 50UTR
of CTDSP2 as a promoter of ﬁreﬂy luciferase. Stronger luciferase
activity was found in the mir-26-1 promoter reporter-transfected
RAW264.7 cells than in control vector-transfected cells, however,
the luciferase activity was suppressed after treating with LXR
agonist T0901317 (Fig. 2D). The above results indicated that the
mir-26-1 promoter reporter worked very well and LXR regulated
miR-26a expression transcriptionally. Taken together, thern blot assay for HA in pBABE or LXRa-HA-pBABE retrovirus infected and puromycin
b-Actin was taken as a loading control, the data are one representation for three
lls were treated with DMSO or LXR agonist T0901317 (1 lM) for 24 h, qPCR assays
cells described in (B, C) was detected by qPCR. (F, G) miR-26a relative expression in
b-actin mRNA, miR-26 was normalized to U6 mRNA. Data are mean ± S.E.M. of three
Fig. 2. LXR-speciﬁc regulation of miR-26 was at transcriptional level. (A) RAW264.7
cells were transfected with 10 nMmixture of si-LXRa and si-LXRb, or 10 nM control
siRNA. 24 h later, these cells were treated with DMSO or T0901317 (1 lM) or
GW3965 (1 lM) for another 24 h, miR-26a expression was detected by qPCR assays
and normalized to U6 mRNA. (B, C) THP-1 cells were treated with DMSO or
T0901317 (1 lM) for 24 h, primary mir-26a-1 and mir-26a-2 were detected by
qPCR and normalized to b-actin mRNA. Data of A–C are mean ± S.E.M. of three
independent experiments. ⁄P < 0.05, ⁄⁄P < 0.01. (D) RAW264.7 cells were cotrans-
fected with 500 ng indicated vector and 50 ng pTK-Renilla luciferase plasmids, 24 h
later, these cells were treated with DMSO or T0901317 (1 lM) for another 24 h, the
ﬁreﬂy luciferase was detected and normalized to Renilla luciferase. Data are shown
as mean ± S.D. (n = 6) of one representative experiment. Similar results were
observed in three independent experiments. ⁄⁄P < 0.01.
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inhibition of mir-26a-1 may be the reason for miR-26 downregula-
tion in LXR-activated macrophages.
3.3. Conserved miR-26 binding sites in ABCA1 30UTR and ARL7 30UTR
By using bioinformatic tools for miRNA target prediction
(Targetscan [http://www.targetscan.org] and miRanada [http://
www.microrna.org]), we found that there were binding sites in
the 30UTRs of ABCA1 and ARL7. The binding sites were highly con-
served in mammals including humans, chimpanzees, mice, rats,
rabbits and cows (Fig. 3A and B). Because of the high similarity
of miR-26a and miR-26b, miR-26b was also found to be a potentialmiRNA which targets ABCA1 and ARL7. Therefore, the database
prediction indicated that there were conserved miR-26 binding
sites in ABCA1 30UTR and ARL7 30UTR. Considering the inverse cor-
relation between miR-26 and ABCA1 (and ARL7), we assumed that
miR-26 might target ABCA1 and ARL7, and thus mediate LXR-
dependent cholesterol metabolism. What’s more, we detected the
miR-26a expression level in different mouse tissues and cells,
and found relatively low expression of miR-26 in spleen, liver
and macrophages comparing to the other tissues (Fig. 3C).
Considering that macrophages and liver cells play critical roles in
cholesterol metabolism, the expression pattern of miR-26 implied
its potential functions in the regulation of cellular cholesterol
level.
3.4. miR-26 suppressed ABCA1 and ARL7 via the binding sites located
in their 30UTRs
ABCA1 30UTR, ARL7 30UTR and their respective miR-26 binding
site mutation luciferase reporters were constructed to verify the
database predictions. By cotransfecting with these reporters and
miR-26 mimics or inhibitors into HEK293T cells, we found that
miR-26a mimics inhibited the luciferase activity of the ABCA1
30UTR reporter. However, miR-26a mimics had no effect on the
mutant ABCA1 30UTR reporter, which has no binding site of
miR-26a (Fig. 4A). Consistently, miR-26a inhibitor, a synthetic
RNA which degrades the endogenous miR-26a, promoted
the luciferase activity of ABCA1 30UTR reporter without altering
the luciferase activity of the mutant ABCA1 30UTR reporter
(Fig. 4B). ARL7 was also a predicted target of miR-26, similar to
the ABCA1 reporter, we found that miR-26a mimics promoted
and miR-26a inhibitors inhibited the luciferase activity of ARL7
30UTR, while miR-26a mimics or miR-26a inhibitors did not alter
the luciferase activity of mutant ARL7 30UTR (Fig. 4C and D). In
conclusion, the luciferase reporter system proved that miR-26
could target ABCA1 and ARL7 via the miR-26 binding sites
located in their 30UTRs.
3.5. miR-26 downregulated ABCA1 and ARL7 expression in LXR-
activated macrophages
To further investigate the cellular effect of miR-26 on its poten-
tial targets ABCA1 and ARL7, we transfected the mouse and human
macrophages with control mimics or miR-26a mimics, or relative
inhibitors, and then treated these cells with LXR agonist. We found
a robust upregulation or degradation of miR-26a after transfection
with miR-26a mimics or miR-26 inhibitor, respectively (Fig. 5A
and B). Consistent with the ABCA1 30UTR reporter results, overex-
pression of miR-26a inhibited the ABCA1 protein expression in
both human and mouse macrophages, while downexpression of
miR-26a increased ABCA1 protein expression (Fig. 5C). For another
LXR target gene ARL7, a potential target of miR-26a, was also inhib-
ited after miR-26a overexpressing and upregulated after miR-26a
downexpressing (Fig. 5D). Thus, miR-26 downregulated ABCA1
and ARL7 expression in LXR-activated macrophages, which further
indicated that miR-26 could regulate cholesterol metabolism by
targeting ABCA1 and ARL7.
What’s more, miR-26 expression was also affected by dietary
cholesterol in the liver and macrophages. We used LDL to mimics
the dietary cholesterol. In LDL-loaded HepG2 and bone-marrow
derived macrophages, we also found the upregulation of ABCA1
mRNA and downregulation of miR-26 (Fig. S3 A–D), which partially
indicated that dietary cholesterol will affected miR-26 expression
in the liver and macrophages. The results in HepG2 also implied
that miR-26 might also regulate cholesterol metabolism by target-
ing ABCA1 in liver cells.
Fig. 3. miR-26 target prediction and miR-26 expression in different tissues. (A) The seed regions of miR-26a and miR-26b were complementary to the ABCA1 30UTR. The
binding site in ABCA1 30UTR were very conserved among the mammals. (B) The seed regions of miR-26a and miR-26b were complementary to the ARL7 30UTR. The binding
site in ARL7 30UTR were very conserved among the mammals. (C) miR-26 expression level in different mouse tissues and cells were detected by qPCR and normalized to b-
actin mRNA. Data are shown as mean ± S.E.M. of three independent experiments.
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cholesterol efﬂux
ABCA1 and ARL7 are important target genes of LXR and
participate in the regulation of cellular sterol homeostasis. To
determine whether miR-26 could modulate the efﬂux of cellular
cholesterol, we transfected RAW264.7 cells with control mimics
or miR-26a mimics. We then incubated the transfected cells with
[3H]-cholesterol in the presence or absence of ligands for LXR to
induce ABCA1 and ARL7. Interestingly, altering miR-26a levels
produced no differences in total cellular cholesterol content or
[3H]-cholesterol uptake (Fig. S4 A and B). The ability of the cells
to efﬂux the radiolabeled sterol to BSA, ApoAI and FBS was ana-
lyzed 6 h later. We found that miR-26a overexpression resulted
in reduced cholesterol efﬂux to ApoAI or FBS after activation of
LXR (Fig. 6A). Thus, miR-26a overexpression decreases cholesterol
efﬂux. Conversely, silencing miR-26a by miR-26a inhibitor resulted
in enhanced LXR-dependent cholesterol efﬂux in RAW264.7 cells
(Fig. 6B). Taken together, miR-26 could regulate cholesterol metab-
olism by suppressing cholesterol efﬂux, by targeting ABCA1 and
ARL7.
In conclusion, we found an inverse correlation between miR-26
and two of the LXR target genes, ABCA1 and ARL7. miR-26 couldcontrol the LXR-dependent cholesterol efﬂux by targeting ABCA1
and ARL7.
4. Discussion
LXRs are nuclear receptors that play critical roles in the tran-
scriptional control of cholesterol metabolism. Once activated, LXRs
induce an array of genes involved in cholesterol absorption, efﬂux,
transport, and secretion. LXRs are ligand-dependent transcription
factors that form permissive heterodimers with the retinoid X
receptor (RXR), and the complex can be activated by ligands of
either partner. Ligand-binding to LXR induces a conformational
change that facilitates coactivator-for-corepressor-complex
exchange and transcription of target genes that have the LXR-
responsive elements (LXRE) [40]. Ligand activation of LXRs also
inhibits transcription from the promoter of certain genes (e.g.,
proinﬂammatory cytokines) that have no LXREs, a phenomenon
referred to as trans-repression. Here, we found that miR-26, an
LXR-suppressed gene, inhibited the two LXR target genes. We
described an alternative mechanism: Ligand activation of LXRs
not only induces a battery of their target genes, but also inhibit
some suppressors such as miRNAs to enhance the LXR-dependent
metabolic regulation.
Fig. 4. miR-26 targeted ABCA1 and ARL7 30UTR in reporter system. (A, B) HEK293T cells were cotransfected with 80 ng wild type (wt) or mutant ABCA1 30UTR ﬁreﬂy
luciferase reporter plasmids, 10 ng pTK-Renilla luciferase plasmids, together with control (Ctrl) mimics or miR-26a mimics, control (Ctrl) inhibitor or miR-26a inhibitor (ﬁnal
concentration: 20 nM) as indicated. After 24 h, ﬁreﬂy luciferase activity was measured and normalized to Renilla luciferase activity. (C-D) HEK293T cells were cotransfected
with 80 ng wild type (wt) or mutant ARL7 30UTR ﬁreﬂy luciferase reporter plasmids, 10 ng pTK-Renilla luciferase plasmids, together with control (Ctrl) mimics or miR-26a
mimics, control (Ctrl) inhibitor or miR-26a inhibitor (ﬁnal concentration: 20 nM) as indicated. After 24 h, ﬁreﬂy luciferase activity was measured and normalized to Renilla
luciferase activity. Data are mean ± S.D. (n = 6) of one representative experiment. Similar results were observed in three independent experiments. ⁄⁄P < 0.01.
Fig. 5. miR-26 targeted ABCA1 and ARL7 in LXR-activated macrophages. RAW-LXRa cells or THP-1 cells were transfected with control mimics or miR-26 mimics (A), control
inhibitor or miR-26a inhibitor (B), After 24 h, the transfected cells were treated with LXR agonist T0901317 (1 lM) for another 24 h. (A, B) qPCR detection of miR-26a in
transfected and T0901317 treated cells. miR-26a was normalized to U6. Data are mean ± S.E.M. of three independent experiments. ⁄⁄P < 0.01. (C-D) Western blot assay for
ABCA1 (C) and ARL7 (D) in transfected and T0901317 treated cells. b-Actin as a loading control, and the data are one representation of three independent experiments.
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Fig. 6. miR-26 inhibited cholesterol efﬂux in vitro. Cholesterol efﬂux assay in
RAW264.7 cells transfected with control (Ctrl) mimics or miR-26a mimics (A), or
with control (Ctrl) inhibitor or miR-26 inhibitor (B). After 24 h, the cells were
washed and incubated for 16 h in media supplemented with [3H]-cholesterol
(1 lCi/ml) in the presence or absence of LXR agonist T0901317 (1 lM) for 24 h. 16 h
later, fresh media supplemented with BSA (0.2%), ApoAI (15 lg/ml), or FBS (20%)
was added to the cells. Radioactivity in the media and in cell lysates was measured
6 h later. The percentage of efﬂux is expressed as dpm in the media versus total
dpm (media + cells). Data are mean ± S.D. (n = 6) of one representative experiment.
Similar results were obtained in three independent experiments. ⁄P < 0.05,
⁄⁄P < 0.01.
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tional regulators of genes involved in cholesterol metabolism. Sev-
eral reports have shown that miR-33 regulates cholesterol efﬂux
and HDL biogenesis by downregulating the expression of the ABC
transporter, ABCA1 and ABCG1 [25–28]. It is very intriguing that
the miR-33a and miR-33b are embedded in Srebp2 and Srebp1,
two critical transcription factors in regulating fatty acid and cho-
lesterol synthesis and uptake, respectively. Ramirez et al. recently
reported miR-758 as a novel miRNA that posttranscriptionally con-
trols ABCA1 and regulates macrophage cellular cholesterol efﬂux to
apoA1, opening new avenues to increasing apoA1 and raising high-
density lipoprotein levels [24]. In our study, we have also found
that miR-26, an LXR-suppressed miRNA, plays a role in cholesterol
efﬂux by targeting ABCA1 and ARL7. Although it is not so clear how
miR-26 was repressed by ligand activation of LXR, we have pro-
vided a new member that mediates the LXR-dependent cholesterol
metabolic regulation.
miR-33 can target multiple genes such as ABCA1, ABCG1, and
NPC1 in cholesterol metabolism, CROT, APT1A, HADHB and AMPK
in fatty acid oxidation, as well as SIRT6 and IRS2 in glucose metab-
olism [41]. It seems that a single miRNA may regulate a physiolog-
ical or pathological activity by targeting several related genes in
the same pathway or in the same process. Another example is
miR-146, which can regulate the innate immune response by
targeting TARF6, IRAK1 and IRAK2 simultaneously [42,43]. Thus,
miR-26 targeting ABCA1 and ARL7, the important regulators of
cholesterol efﬂux, may have its physiological signiﬁcance.
The in vivo function of miR-26 in the regulation of cholesterol
metabolism should be further investigated. The role of miR-26 in
liver cells is also a very interesting issue which needs to be
unveiled.miR-26, a newly identiﬁed LXR responsive miRNA, may confer
the signal from LXR activation, or feedback regulate the LXR down-
stream signaling, as well as participate in other lipid metabolism
processes. All the above issues need to be further determined.
Meanwhile, given that miR-26 is a regulator of cholesterol efﬂux,
miR-26 may serve as a potential therapeutic target of cholesterol
metabolic disorders.
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